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Objectives: This study aims to systematically review evidence published on the safety of Sino-implant (II) [SI (II)] among women with
medical conditions or characteristics identified by the World Health Organization for eligibility for contraceptive use.
Study design:We searched PubMed, WEIPU, CNKI and Wanfang to identify all relevant evidence published in peer-reviewed journals from
1991 through 2014 regarding the safety of SI (II). We considered studies among women with medical conditions or other characteristics, such
as age and parity, as direct evidence and studies among healthy women or a general population of women as indirect evidence.
Results:We identified 108 articles of which 9 met our inclusion criteria. Among women with medical conditions, no evidence was identified
for the outcomes of interest, including serious adverse events or outcomes related to medical conditions. Among healthy women, evidence
regarding efficacy of SI (II) for women weighing ≥70 kg was conflicting; one study showed an increased pregnancy rate and another showed
no relationship. Women with menorrhagia did not experience worsened symptoms and may benefit from SI (II) use. Healthy women using SI
(II) were no more likely than users of other methods to gain weight, develop elevated blood pressure, have abnormal liver or bone density
tests or develop ovarian cysts or uterine myomas.
Conclusions: Evidence among healthy women suggests SI (II) is safe and had health outcomes similar to those of other levonorgestrel
implants. Studies were limited and conflicting regarding efficacy for women ≥70 kg. All included studies were conducted in China, limiting
generalizability.
© 2016 Elsevier Inc. All rights reserved.Keywords: Sino-implant II; Contraceptive implant; Levonorgestrel implant; Contraceptive safety1. Introduction
Contraceptive implants are highly effective long-acting
reversible contraceptives that are safe for most women [1] and
are in general highly acceptable to those who use them [2].
Sino-implant (II) [SI (II)] is a 2-rod subdermal contraceptive
implant that contains the progestin levonorgestrel (LNG) (75☆ The findings and conclusions in this report are those of the authors and
do not necessarily represent the official position of the World Health
Organization or US Centers for Disease Control and Prevention.
☆☆ Use of trade names and commercial sources is for identification only
and does not imply endorsement by the US Department of Health and
Human Services.
⁎ Corresponding author.
E-mail addresses: sharonphillipsmd@gmail.com,
sjp633@mail.harvard.edu (S.J. Phillips).
http://dx.doi.org/10.1016/j.contraception.2016.05.004
0010-7824/© 2016 Elsevier Inc. All rights reserved.mg per rod, 150 mg total) [3]. SI (II) has been shown to
produce a mean serum concentration of LNG of 0.59 ng/mL in
the first month, declining to 0.28 ng/mL by the 12th month
after insertion [4], and 0.21 ng/mL by the fifth year after
insertion [5]. Therefore, it may be expected to have similar
characteristics to both the 6-rod LNG-containing implant
(Norplant®, consisting of 6 silicon capsules, each containing
36 mg of LNG; no longer in production) and the 2-rod
LNG-containing implant (Jadelle®, consisting of 2 silicon
rods, each containing 75 mg of LNG)1. It may also have
similarities to another progestin-only implant containing
etonogestrel (Implanon® and Nexplanon ®, consisting of 1
polymer rod containing 68 mg etonogestrel) [6]. In addition to
being used in contraceptive implants, LNG, also known as1 Note that brand names will be used for clarity for the duration of this
review; their use does not imply endorsement.
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progestins used in combined oral contraceptives. LNG causes
changes in the cervical mucus that prevent penetration by
sperm and also inhibits ovulation and leads to altered
endometrial development and ovulatory dysfunction in most
women [8,9].
SI (II) is manufactured by Shanghai Dahua Pharmaceu-
tical Co, Ltd. (Shanghai, China), is approved for 4 years of
use and is currently registered in over 20 countries [10]. SI
(II) has been used by millions of women worldwide,
primarily in China and Indonesia but also in several African
settings [3].
A systematic review of randomized controlled trials to
assess the efficacy of SI (II) found that, in four randomized
clinical trials (RCTs) with a total of over 15,000 women
assigned to the method, pregnancy rates in the first year of
use ranged from 0% to 0.1%, and cumulative pregnancy
rates through year 4 ranged from 0.9% to 1.06% [3]. These
pregnancy rates are similar to those reported for other LNG
implants [2] and the etonogestrel implant [11].
We conducted a systematic review of published evidence
on the safety of SI (II) for women of reproductive age
according to the medical conditions and characteristics
identified by World Health Organization (WHO) for
eligibility for contraceptive use in preparation for a technical
meeting to update WHO's Medical Eligibility Criteria for
Contraceptive Use (MEC) [1] and to consider the addition of
SI (II) to the methods included in the MEC. This review
focuses on two main questions. First, for women with
medical conditions or other characteristics, do SI (II) users
have an increased risk for adverse events compared with
nonusers? Second, because we anticipated finding few
studies to answer this question, we also sought to draw
upon the large body of evidence on the safety of other LNG
implants to determine whether SI (II) demonstrates that it is
similar with respect to safety to other contraceptive implants.
If so, users of the method can follow the MEC guidance
already available for implants.2. Methods
This review was prepared using PRISMA guidelines for
the conduct of systematic reviews [12]. We searched
PubMed for references in peer-reviewed journals in any
language relating to SI (II) from 1991 (5 years before the
product was approved for general use in China) through
December 2014. Because most of the studies on SI (II) have
been conducted in China and published in the Chinese
medical literature, we also searched WEIPU, CNKI and
Wanfang, indexes for Chinese medical journals. In PubMed,
we used the terms “sino implant OR sino-implant OR
sinoplant” AND “contracept*”. In WEIPU, we used similar
search terms in standard Chinese. We also contacted the
authors of a previous review of RCTs assessing the efficacy
of SI (II) [3] and cross-referenced the articles we identifiedwith the list of articles considered for that review and
hand-searched the reference lists of identified articles.
2.1. Study selection
For this review, studies of any design were included. The
title and abstract from each article identified were reviewed
to determine whether an article satisfied the review inclusion
criteria. English language results were screened by one
author (SJP) and a native speaker screened Chinese language
results. We sought articles to answer our primary question:
among women with medical conditions, such as hyperten-
sion or menorrhagia, or other specific characteristics, such as
age and parity, do those who use SI (II) have an increased
risk for adverse events (e.g. worsened menorrhagia or
worsened hypertension) compared with those who do not use
SI (II)? Studies that answered this question were considered
direct evidence. The ideal comparison group would be
women using no contraception or nonhormonal contracep-
tion. We were also interested in whether SI (II) has a similar
safety profile to other contraceptive implants; therefore, we
included studies that examined users of other implants as the
comparison group. Although Norplant® is no longer
available on the market because there is a large body of
evidence on its safety [13], we considered comparisons with
this method to be informative. If studies show that SI (II) and
Norplant® have similar safety profiles in comparative
studies, we may be able to extrapolate to make conclusions
about the safety of SI (II).
We excluded articles referring only to implants other than
the SI (II), including articles only studying SI (I), Jadelle®
and Norplant®. Because this article focuses on safety, we
also included only comparative studies to examine whether
rates of adverse events were different in SI (II) users than in
nonusers. Finally, we excluded publications that reported on
a subset of data that was published elsewhere as a larger
analysis if that larger analysis was included in the review.
Because we anticipated that we might find limited or no
direct evidence, we also sought studies with indirect
evidence that answered a secondary question: among healthy
women or among a general population of women of
reproductive age, do those who use SI (II) have an increased
risk for serious adverse events or other relevant outcomes
compared with those who do not use SI (II)? As with those
studies providing direct evidence, the comparison group
could include users of nonhormonal contraceptive methods,
other hormonal methods or other implants. For the indirect
evidence, in addition to serious adverse events, we also
included studies that examined outcomes that might be
relevant to medical conditions, such as information on
weight, blood pressure or vaginal bleeding changes after
initiation of the method, as well as variations in efficacy
related to weight; however, such studies were only included
if they directly measured these outcomes and included a
comparison group and were excluded if only self-reported
symptoms were included.
Table 1
RCTs
Author, year
Support
Study design
Population
Outcome
Follow-up
Results Strengths, weaknesses Quality
Fang 1997 [20]
Source of funding not stated
RCT
19,673 women
aged 17–40 years,
with at least 1 child,
smoking less than
10 cigarettes/day
9739=SI (I)
9934=SI (II)
Serious adverse events
2 years
Ectopic pregnancy
SI (I): 1 case, SI (II): 3 cases
(statistics not reported)
Physical examination
No difference between groups at any time
point in incidence of breast, pelvic or
cardiovascular abnormalities on physical
examination (all abnormalities
b0.3% incidence)
Strengths
–Appropriate analyses
–Low loss to follow-up (5.7% over 2 years)
Weaknesses
–No description of
allocation concealment
or randomization procedures
–Unclear how women who
discontinued or were LTFU
were analyzed
I, intermediate
Ni 1998 [18]
Source of funding not stated
RCT
300 women,
married, parous,
aged under 40 years,
100=SI (I)
100=SI (II)
100=Norplant®
Weight change
2 years
Weight
All groups increased, but no significant
difference among groups; SI (I): 1.4 kg;
SI (II): 0.86 kg; Norplant®: 0.77 kg
Among women weighing more than 70 kg
at the time of implant insertion, weight
change ranged from −10 kg to +4 kg at
24 months
Weaknesses
–No description of randomization
procedures or allocation concealment
–Loss to follow-up not reported
–Unclear how women who
discontinued or were LTFU were analyzed
I, low
Zhang 1998 [14]
Source of funding not stated
RCT
1846 women
≤40 years old,
parous, smoking
≤10 cigarettes/day
919=SI (I)
927=SI (II)
Weight change
Blood pressure change
2 years
Weight
Increased in both groups compared with
preinsertion (0.63 kg SI (I), 0.72 kg SI (II),
pb .05 for paired t test, comparative between
groups statistics not presented)
Blood pressure
Small, statistically significant increase in
systolic blood pressure in both groups; diastolic
blood pressure decreased in SI (I) group,
unchanged in SI (II) group
Strengths
–Low loss to follow-up (b4% at 2 years)
–Appropriate analyses
Weaknesses
–No description of randomization
procedures or allocation concealment
–Unclear how women who discontinued
or were LTFU were analyzed
I, intermediate
Qi 2002 [17]
Source of funding not stated
RCT
2297 women
Phase I:
100=SI (I)
100=SI (II)
100=Norplant®
Phase II:
1000=SI (I)
1000=SI (II)
2 excluded for
noncompliance
Pregnancy; continuation;
removal for various reasons
5 years
Phase I
Ectopic pregnancy
No ectopics
Phase II
Ectopic pregnancy
SI (I): 1 ectopic, SI (II): no ectopics
Changes in blood pressure,
weight, hemoglobin
2 participants had increased blood pressure;
all others were normal; average body weight
increased but was the same between CLa
and SI (II) groups; no significant difference in
hemoglobin or platelets before
Strengths
–Low loss to follow-up (0.5% over 5 years)
–Appropriate analyses
Weaknesses
–No description of allocation concealment
or randomization procedures
–Unclear how women who discontinued or
were LTFU were analyzed
–Unclear if blood pressure was checked
on all participants
–Unclear when changes in
hemoglobin measured
I, intermediate
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and after placement, though
unclear when tests occurred
(pN .05) (Hemoglobin tested on
a subset of 300 participants)
Xing 2002 [15]
Source of funding not stated
RCT
7941 women,
aged 17–40 years
parous, nonsmoker
orb10 cigarettes/day
3932=SI (I)
4009=SI (II)
Removal for medical reasons;
efficacy based on weight
5 years
Removal for medical reasons
SI (II) group less likely to
remove for medical reasons
(2.1 vs. 1.5, pb .05)
Weight
69 pregnancies (86% among
users of SI [II]). Pregnancy rate
for women ≥70 kg at baseline
2.19 vs. 0.74 for women b60 kg
(statistical analysis not reported).
No relation between duration of
implant use and pregnancy
among women ≥70 kg (statistical
analysis not reported)
Strengths
–Low loss to follow-up (6.9% over 2 years,
7.7% over 5 years)
–Appropriate analyses
Weaknesses
–No description of randomization procedures
–Unclear how women who discontinued or
were LTFU were analyzed
I, intermediate
Fan 2004 [21]
National Population and
Family Planning
Commission
RCT
2999 women,
aged 18–40 years,
parous
1001=SI (I)
1000=SI (II)
998=Norplant®
Removal for medical
reasons; renal/hepatic
function tests; efficacy
based on weight
5 years
Ectopic pregnancy
No ectopic pregnancies in
any group
Removal for medical reasons
Including headache, skin problems,
mammary hyperplasia, cardiovascular
disease, uterine tumor, ovarian cyst,
weight increase, diabetes, cancer,
pulmonary cardiomyopathy: no
difference among groups (pN .05)
Hepatic function
50 cases selected from each group
for hepatic and renal tests; all indices
normal at 1, 2 and 5 years postinsertion
(results not reported)
Weight
No relation seen between weight and
pregnancy (only 8 pregnancies occurred);
unclear how this analysis was performed
Strengths
–Low loss to follow-up (0.2% over 5 years)
Weaknesses
–No description of allocation concealment or
randomization procedures
–Unclear how cases were selected for
measurement of hepatic function
–Pregnancy/weight analysis not stratified
by method used
–Unclear how women who discontinued
or were LTFU were analyzed
I, intermediate
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Table 2
Observational studies
Author, year
Support
Study design
Population
Outcome
Follow-up (if applicable)
Results Strengths
Weaknesses
Quality
Han 1998 [22]
Source of funding
not stated
Prospective cohort
89 women, parous,
with normal menstruation
29=SI (I)
30=SI (II)
30=Norplant®
Change in mean blood
loss, hemoglobin
1 year
Mean blood loss
All groups had decreased MBL after
implantation compared with before
SI (II) users had significantly decreased
MBL at 3rd cycle compared with before
implantation; no significant difference at
6th or 12th cycle, although both SI (I)
and Norplant® users had significantly
decreased MBL at 12th cycle
Mean blood loss among women with
MBL≥80 mL preinsertion
MBL decreased from mean 113 mL to 51
at 3rd cycle (pb .05), 106 at 6th cycle
(pN .05), 61 at 12th cycle (pb .05)
Hemoglobin changes
Hemoglobin increased in all groups,
including SI (II), from preinsertion
to 12th cycle; no significant
difference between groups. Among
women with MBL≥80 mL, Hb
increased from mean 109
to 133 g/L (statistics not provided)
Strengths
–Rigorous, quantitative measurement
of mean blood loss
Weaknesses
–Little description of methods for
recruitment into study
–Key information not presented stratified
by method used
–Loss to follow-up not described
II-2, low
Shen 1998 [16]
Source of funding
not stated
Cross-sectional
166 women using method
for ≥3 years
37=SI (I)
41=SI (II)
45=Norplant®
43=nonuser (no hormonal
contraceptives in prior year)
Bone mineral density
and surrogate markers
of bone health
Bone mineral density
No difference among groups
Bone metabolism markers
SI (II) no different from control
Hydroxyproline/creatinine and calcium/
creatinine ratio higher in Norplant®
group than other groups (pb .01)
(indicative of bone formation);
Serum calcium, phosphorus, Alk
phosphatase, osteocalcin (BGP): no
difference among groups
Estrogen
No difference among groups
Osteocalcin (BGP)
SI (II) no difference from control
Osteocalcin lower vs. control in
women aged 35–39 years and
≥40 years using Norplant®
Strengths
–Compared with both other implants
and nonhormonal control
–Methods well-described
Weaknesses
–Cross-sectional design
–Multiple comparisons without a
priori explanations
II-2, low
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Evidence from each study included for the review was
summarized on a standard abstract form developed for the
systematic review process. All Chinese language studies
were translated to English. Studies were abstracted by one
author (SJP) and verified by a second author (PSS). We did
not abstract data on overall contraceptive efficacy (i.e. other
than efficacy in relation to body weight) or discontinuation
due to side effects such as menstrual problems as a previous
systematic review of randomized trials has already estab-
lished the effectiveness and acceptability of the method, as
compared with other LNG implants [3].
The quality of the evidence presented in each individual
study was assessed according to the methods of GRADE
[14]. Briefly, RCTs were rated as high quality if there were
no serious flaws in study quality, including complete
reporting of study recruitment methods, adequate random-
ization procedures and allocation concealment, presence of
low and nondifferential loss to follow-up and the use of
appropriate analytic methods. RCTs with at least one serious
flaw in execution or reporting were rated as intermediate if
those flaws were deemed unlikely to bias the results. RCTs
with multiple flaws in execution or reporting, in which the
flaws were deemed likely to bias the results, were rated as
low quality. RCTs with multiple flaws in execution or
reporting, with at least one other serious threat to validity,
were rated as very low quality. Observational studies were
rated as high quality if they had no threats to validity and
reported strong associations; as intermediate quality if they
reported a strong, consistent association and had no plausible
confounders; as low quality if they had no serious flaws in
study design but otherwise failed to meet the above criteria;
and as very low quality if they had serious flaws in design or
execution.
We did not perform metaanalysis for most outcomes due
to the heterogeneity of reporting of these outcomes and the
small number of studies reporting on each outcome nor did
we do so for the outcome of ectopic pregnancy due to the
rarity of the outcome.3. Results
Based upon the search, 107 articles were identified (98
through WEIPU, 9 through PubMed). Of these 107 articles,
we reviewed the full text of 20 and found 8 that met our
inclusion criteria [15–22]. One additional study was added
after hand-searching the reference lists of relevant articles
[23], for a total of nine included studies. Eight of these
studies were originally published in Chinese and were
translated. Among the included articles, six were RCTs, two
were prospective observational studies and one was a
cross-sectional study. Three studies reported on serious
adverse events [18,21,22], while the others reported on
outcomes that might be relevant to women with medical
222 S.J. Phillips et al. / Contraception 94 (2016) 216–225conditions (such as changes in blood pressure, menstrual
bleeding, hemoglobin or liver function tests). Tables 1 and 2
provide a summary of the objectives, study design, study
population, main results, strengths, weaknesses and quality
grade for each of the clinical studies included in this
systematic review.
3.1. Direct evidence
We identified no comparative studies that provided direct
evidence among women with medical conditions on the
association between use of SI (II) and serious adverse events
or outcomes relevant to medical conditions.
3.2. Indirect evidence: Serious adverse events
We identified three RCTs that reported on serious adverse
effects among healthy women using SI (II) [18,21,22]. One
study compared women using SI (II) with those using the
6-rod Chinese-made LNG implant (also known as the CLa
implant or Sino-implant (I), hereafter referred to as SI [I])
[21]. In this study, 19,673 parous women aged 17–40 years
were randomly allocated to one of these two methods and
followed for 24 months. There was one ectopic pregnancy in
the SI (I) group compared with three in the SI (II) group
(statistics not reported). There were no statistically signifi-
cant differences between groups in breast, pelvic or
cardiovascular abnormalities as assessed by physical exam-
ination. Another RCT followed 1000 women randomly
allocated to either SI (I) or SI (II) [18] for 5 years. There was
one ectopic pregnancy in the SI (I) group and there were no
ectopic pregnancies in the SI (II) group. A third RCT
enrolled 1001 women to use SI (I), 1000 to use SI (II) and
998 to use Norplant® and followed them for 5 years [22]. No
ectopic pregnancies occurred in any of the three groups, and
there were no differences between groups in the frequency of
removal for any medical reasons, including mammary
hyperplasia, cardiovascular disease, cancer, uterine tumors,
ovarian cysts or pulmonary cardiomyopathy.
3.3. Indirect evidence: Outcomes relevant to women with
medical conditions
We identified seven studies that reported on healthy
women using SI (II) that provided indirect evidence on
outcomes considered relevant to women with medical
conditions [15–20,22,23]. Five of these had information
either about method effectiveness related to weight at study
initiation [16,22] or weight change while using SI (II)
compared with another method [15,18,19]; two, about
changes in blood pressure while using SI (II) compared
with another method [15,18]; two, about changes in
hemoglobin, platelets or mean blood loss [18,23]; one,
about bone mineral density and markers associated with
bone mineral density [17]; one, about hepatic and renal
function tests [22]; and one, about benign ovarian cysts or
uterine leiomyomas [20].3.3.1. Effect of body weight on contraceptive effectiveness
Two studies analyzed efficacy rates based on the weight
of the woman at study initiation; neither provided separate
estimates by implant type, although the majority of
pregnancies in both studies occurred among women using
SI (II). One study was an RCT that randomized 7941 parous
women aged 17–40 years to either SI (I) or SI (II) and
followed them for 5 years [16]. There were a total of 69
pregnancies (of which the majority, 86%, were among users
of SI [II]). Among those who became pregnant, women who
weighed ≥70 kg at baseline had three times the pregnancy
rate of those who weighed b60 kg (statistical analysis not
reported); this was based on four pregnancies in the group of
women weighing ≥70 kg. The authors reported that there
was no relation between the amount of time the implant was
used and the risk of pregnancy among those who weighed
≥70 kg (statistics not reported). Another RCT (also
mentioned above) with 2999 women who used either SI (I)
or SI (II) reported that there was no relation between weight
and pregnancy. This was based upon eight pregnancies that
occurred (of which the majority, 63%, occurred in the SI (II)
group; statistical analyses not reported) [22].
3.3.2. Weight change
Four studies (three RCTs and one cohort study) reported
on weight change among users of SI (II) compared with users
of other progestin-only methods [15,18,19] or nonhormonal
or no method [20]. One RCT included 2297 users of either SI
(I) or SI (II) and found that mean weight increased in both
groups over the 5 years of the study, but the difference
between groups was not statistically significant [18].
Another RCT included 300 women using SI (I), SI (II) or
Norplant®. Mean weight increased in all groups but there
was no significant difference between groups [19]. This
study reported on the subgroup of women weighing ≥70 kg
at study initiation and found that weight change over 2 years
ranged from a decrease of 10 kg to an increase of 4 kg but did
not compare the weight change in this group to that among
women who weighed less than 70 kg at study initiation. A
third RCT including 1846 women using either SI (I) or SI (II)
found that both groups gained a modest amount of weight
over 2 years (b1 kg; between-group comparative statistics
not reported) [15]. A cohort study that included 315 users of
SI (II) and 302 women using either no method or no
hormonal method found no difference in weight between
groups at study initiation [20]. Over the 3 years of
observation, both groups gained a modest amount of weight;
however, nonusers gained significantly more weight than
users of SI (II) (mean gain 2.7 vs. 1.3 kg, pb .05).
3.3.3. Mean menstrual blood loss, hemoglobin
One RCT reported on both menstrual blood loss and
change in hemoglobin [23]; another provided information on
change in hemoglobin and platelets [18]. One of these RCTs
included 89 women (mostly with normal levels of menstrual
blood loss, although a subset met criteria for menorrhagia)
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and followed for 1 year [23]. SI (II) users had significantly
decreased mean blood loss compared with baseline at cycle 3
but no significant difference at cycle 6 or 12. Norplant® and
SI (II) users had significantly decreased mean blood loss at
cycle 12 compared with baseline; however, there was no
statistically significant difference between study groups at
any time point. In the subgroup of women with menorrhagia
(mean menstrual blood loss≥80 mL, n=9), mean blood loss
decreased from 112.8 to 60.5 mL by cycle 12 (pb .05);
estimates were not provided separately by implant group.
Mean hemoglobin levels increased in all groups in the study,
including among those using SI (II), in whom mean
hemoglobin increased from 111.1 g/L to 137.6 g/L at 1
year (pb .001). Mean hemoglobin levels also increased in the
subgroup of women with menorrhagia, from a mean of 109.2
g/L to 133.4 g/L (mean hemoglobin at cycle 12 not
significantly different among those with menorrhagia
compared with those without menorrhagia; estimates not
reported stratified by method). In another RCT including
2297 participants, a subset of 300 [allocated to SI (I), SI (II)
or Norplant®] had their hemoglobin checked before and after
placement (time interval not reported) and no significant
differences were found between groups [18].
3.3.4. Bone mineral density
One cross-sectional study assessed bone mineral density
and serum markers associated with bone formation [17]. In
this study, 166 women who had used SI (I), SI (II) or
Norplant® for at least 3 years were compared with women
who had used no hormonal contraceptive for at least 1 year.
No differences were found among the groups in terms of
bone mineral density, serum calcium, phosphorus, alkaline
phosphatase, osteocalcin or estrogen. Additionally although
the hydroxyproline/creatinine and calcium/creatinine ratios
(indicative of bone formation) were higher in Norplant®
users than nonusers (pb .01), no such difference was found
among SI (II) users. There was no effect of age on
osteocalcin levels among women using SI (II), although
osteocalcin levels were lower both in women aged 35–39
and ≥40 years using Norplant®.
3.3.5. Blood pressure
Two studies were identified that compared blood pressure
between users of SI (II) and users of other methods. One is a
previously described RCT [18] that compared blood pressure
among women randomized to SI (I), SI (II) or Norplant®; the
other is a previously described cohort study that compared
blood pressure among users of SI (II) and women using no
hormonal method [20]. In the RCT, two women who were
normotensive at study initiation were reported to have
increased blood pressure during the study, although the
allocation status of these participants is not specified and it is
not clear whether blood pressure was measured on all 2297
women or only a subset of 300 women [18]. In the
observational study, which followed 617 users of either SI(II) or no hormonal method, both systolic and diastolic blood
pressures were higher in nonusers than SI (II) users after 3
years (pb .05).
3.3.6. Hepatic function
One previously mentioned RCT checked hepatic function
tests at 1, 2 and 5 years postinsertion in a subset of the nearly
3000 women randomized to SI (I), SI (II) or Norplant® [22].
Among the 50 cases selected from each group for testing,
there were no abnormalities in any of the groups (results not
reported).
3.3.7. Benign ovarian cysts and leiomyomas
One cohort study, further described above, assessed the
development of ovarian cysts and leiomyomas yearly for 3
years among over 600 women using either SI (II) or using no
method or no hormonal method [20]. Women using SI (II)
were more likely to develop ovarian cysts evident on
ultrasound and were less likely to develop leiomyomas than
nonusers of hormonal methods. All the ovarian cysts
resolved spontaneously.4. Discussion
SI (II) is in use in multiple countries, with positive reports
of the feasibility and acceptability of its use in routine service
delivery in varying locations [24,25]. It uses the same
quantity of hormone, 150 mg LNG, as another implant that is
already included in the MEC (Jadelle®). SI (II) and other
LNG-containing implants are the same with respect to
hormone formulation, quality profile [26] and daily release
rates [27], {although in vitro tests have shown that SI (II) has
less of a “burst effect” than Norplant® [28]}. SI (II) is among
the most effective contraceptive methods available, with
5-year cumulative pregnancy rates estimated between 0.7%
and 2.1% [3].
Although evidence is available for the efficacy of SI (II),
evidence for the safety of the method for women with
medical conditions or other characteristics is scarce. We
sought to determine if women with medical conditions or
other characteristics, such as age and parity, using SI (II)
have an increased risk for adverse events compared with
those who do not use SI (II) but were unable to identify any
studies that addressed our primary question. We did however
identify studies that provided indirect evidence by reporting
on serious adverse events, weight change among method
users, effectiveness related to weight, bone mineral density,
menstrual blood loss and hemoglobin changes, lipid and
liver profile changes and benign ovarian cysts and uterine
tumors among healthy women.
4.1. Serious adverse events
Three studies reported on serious adverse events, such as
ectopic pregnancy or method discontinuation due to medical
reasons, among healthy women using SI (II) compared with
women not using SI (II) [18,21,22]. The results from these
224 S.J. Phillips et al. / Contraception 94 (2016) 216–225three studies, which were all of intermediate quality, reported
few adverse events and suggested that SI (II) has a similar
safety profile to other LNG-containing implants.
4.2. Other medical conditions
One study found that users of SI (II) gained less weight
than users of nonhormonal or no contraceptives [20] and
three studies found no significant difference between weight
changes of SI (II) users and users of other implants
[15,18,19], although users in most studies tended to gain
weight over time. There was no evidence of declining
effectiveness over time in overweight women [16]. Results
on effectiveness for overweight women were equivocal, with
one study finding it to be decreased [16] among women
weighing ≥70 kg and another finding no relation between
weight and effectiveness among the eight pregnancies that
occurred [22].
Evidence from one cross-sectional study is reassuring
with respect to bone mineral density and surrogate markers
of bone turnover and formation [17]. There was no evidence
of an effect on hepatic function [22] or blood pressure
[18,20]. Although there was an increased likelihood of
developing ovarian cysts among users of SI (II), the cysts
were asymptomatic and users were less likely to develop
uterine fibroids [20].
In addition to the results from the systematic review, we
identified several studies that did not meet our inclusion
criteria due to lack of a comparison group but may be
informative with respect to SI (II) safety among women with
other medical conditions or characteristics, such as age and
parity. A noncomparative study among healthy women
found no change in lipid profiles over time among women
using SI (II) [29]; another noncomparative study found no
difference in total cholesterol, HDL or LDL [30]. One
noncomparative cohort study assessed infant outcomes
among children of breastfeeding mothers using the implant;
all of the 60 infants had weights and heights within normal
ranges over a 6-year period [29]. IQ was over 90 for all
children tested. In one study, 28 HIV-negative users of SI (II)
had were randomized to TDF-FTC for primary HIV
prevention [31]. No pregnancies occurred up to 1 year of
follow-up, and after adjusting for age, BMI and time since
implant insertion, use of TDF-FTC was not associated with
changes in mean LNG concentration compared with those
assigned to placebo. All mean concentrations were above the
minimum LNG concentration reported for efficacy.
4.3. Limitations to the body of evidence
This body of evidence is primarily limited by the absence
of studies on safety of SI (II) use among women with
medical conditions or other characteristics. There were also
several limitations in the quality of the existing indirect
evidence. The six RCTs included in this review were
generally of intermediate quality. Some of the RCTs had
potential for bias due to failure to report procedures forallocation concealment and randomization sequence gener-
ation [32]. However, bias may be minimized by extremely
low loss to follow-up in all the studies. The three
observational studies included two cohort studies and
one cross-sectional study of low to very low quality;
limitations of the observational studies included poor
description of study methods [23], use of multiple compari-
sons without adjustment [17] and high and differential loss to
follow-up [20].
The body of evidence and this systematic review have
limited generalizability, given that all the studies included in
the review were conducted in China. Two studies have been
published on SI (II) that included women from outside
China. Although they did not have a comparison group and
do not inform our primary question regarding the safety of SI
(II) for women with medical problems, one study in
Madagascar showed high efficacy and acceptability and no
pregnancies [24] and another in Kenya and Pakistan showed
few adverse events and few pregnancies [25] . This provides
some reassurance that the method would be expected to
behave similarly in non-Chinese women.
An additional limitation on the generalizability of this
body of literature is that women under age 17 years and over
age 40 years, those who were nulliparous or those who had
medical conditions were excluded from most of the studies
identified. This limited our ability to answer our primary
question about the safety of the method for women with
medical problems.
The scope of the problem is unknown, but duplicate
publication is not uncommon in the Chinese literature [33].
We attempted to ascertain the originality of all included
studies, but we may have wrongly included studies that were
duplicates or excluded as duplicates studies that were in fact
original.
In 2014, the WHO Expert Working Group reviewed this
evidence to assess how to add SI (II) to the Medical
Eligibility Criteria [34]. Although the evidence was limited
regarding women with medical conditions, the Expert
Working Group determined that the evidence of similarity
of SI (II) to other LNG implants warranted a recommenda-
tion that SI (II) be equated with Jadelle® for the purposes of
the MEC.5. Conclusions
Multiple studies comparing SI (II) to other LNG implants
found no difference in serious adverse events or for surrogate
markers of disease in healthy women. Limited evidence
suggests that SI (II) is not harmful and may be beneficial for
women with menorrhagia. Studies were conflicting regard-
ing efficacy for overweight women, although very few
pregnancies occurred in absolute terms. The safety and side
effect profile of SI (II) appears to be comparable to that of
other LNG implants. Serious adverse events were uncom-
mon. Evidence was limited to research involving women in
225S.J. Phillips et al. / Contraception 94 (2016) 216–225China. No evidence was identified comparing SI (II) to
nonhormonal or other contraceptive methods.Acknowledgements
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